Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared a post on LinkedIn:
“Hackensack University Medical Center is one of the study locations for first-in-human trial of ML261, a potency-enhanced anti-DLL3 CAR T therapy, in relapsed SCLC and neuroendocrine carcinomas. Learn more about First in Human CART SCL”
Other articles featuring Dr. Velez on OncoDaily.